Date: 2014-09-10
Type of information: Financing round
Company: AM-Pharma (The Netherlands)
Investors: Gilde Healthcare (The Netherlands) - Ysios Capital Partners (Spain) - Kurma Biofund (France) - Abbvie (USA) - BB Biotech Ventures (Switzerland) - Idinvest Partners (France) - Inventages Venture Capital (UK-Switzerland-New Zealand-Bahamas)
Amount: €12.2 million
Funding type: financing round
Planned used: The funds will be used to complete a 290 patient, four-arm, Phase II dose-finding, placebo-controlled, Phase III enabling study of recAP in acute kidney injury (AKI), making it the largest ever therapeutic AKI trial. Additionally, the proceeds of this financing round enable AM-Pharma to continue the oral formulation development of recAP to treat ulcerative colitis (UC) and prepare for Phase II development.
Others: * On September 11, 2014, AM?Pharma, a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors AbbVie, BB Biotech Ventures, Idinvest Partners, Inventages, Kurma Biofund and Ysios Capital also participated in the round.
Therapeutic area: Inflammatory diseases
